Publications by authors named "D J Moliterno"
Impact of ticagrelor with or without aspirin on total and recurrent bleeding and ischemic events after percutaneous coronary intervention: A sub-study of the TWILIGHT trial.
Eur Heart J Cardiovasc Pharmacother
October 2024
Article Synopsis
- The study evaluates the impact of early discontinuation of aspirin in favor of ticagrelor monotherapy on bleeding and ischemic events in patients who underwent percutaneous coronary intervention (PCI).
- Results show that while ticagrelor monotherapy led to significantly fewer bleeding events compared to ticagrelor plus aspirin, the total ischemic events remained similar between the two groups.
- Overall, among high-risk PCI patients, ticagrelor alone was associated with reduced bleeding without increasing the risk of ischemic complications.
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial.
Am Heart J
June 2024
Article Synopsis
- This analysis investigates whether patients with peripheral artery disease (PAD) benefit more from taking ticagrelor alone or in combination with aspirin after undergoing a procedure called percutaneous coronary intervention (PCI).
- The TWILIGHT trial involved patients at high risk for heart issues or bleeding, who were given either aspirin or a placebo alongside ticagrelor after 3 months of dual antiplatelet therapy, with outcomes assessed after 12 months.
- Results showed that while PAD patients faced higher risks of complications, those on ticagrelor monotherapy experienced fewer bleeding complications compared to those on combination therapy, without a rise in heart attack or stroke incidents.
Dual antiplatelet therapy (DAPT) with aspirin and a platelet P2Y12 receptor inhibitor is the standard antithrombotic treatment after percutaneous coronary interventions (PCI). Several trials have challenged guideline-recommended DAPT after PCI by testing the relative clinical effect of an aspirin-free antiplatelet approach-consisting of P2Y12 inhibitor monotherapy after a short course (mostly 1-3 months) of DAPT-among patients undergoing PCI without a concomitant indication for oral anticoagulation (OAC). Overall, these studies have shown P2Y12 inhibitor monotherapy after short DAPT to be associated with a significant reduction in the risk of bleeding without an increase in thrombotic or ischaemic events compared with continued DAPT.
View Article and Find Full Text PDF